Liquid biopsies offer the potential to monitor cancer response and resistance to therapeutics
in near real-time. However, the plasma cell free DNA (cfDNA) level can be low and the …

In current molecular cancer diagnostics, using blood samples of cancer patients for the
detection of genetic alterations in plasma (cell‐free) circulating tumor DNA (ct DNA) is an …

Abstract BACKGROUND Droplet digital PCR (ddPCR) is an emerging technology for
quantitative cell-free DNA oncology applications. However, assay performance criteria must …

The clinical management of cancer has evolved in recent years towards more personalized
strategies that require a comprehensive knowledge of the complex molecular features …

Purpose: Circulating tumor DNA (ctDNA) is increasingly recognized as liquid biopsy to
profile tumor genome. Droplet digital PCR (ddPCR) is a highly sensitive and easily operable …

Introduction: Early detection of cancers through the analysis of ctDNA could have a
significant impact on morbidity and mortality of cancer patients. However, using ctDNA for …

The efficient characterization of genetic and epigenetic alterations in oncology, virology, or
prenatal diagnostics requires highly sensitive and specific high-throughput approaches …

In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …

Breast cancer is the most common cancer affecting women worldwide. It is a malignant and
heterogeneous disease with distinct molecular subtypes, which has prognostic and …

Cancer is one of the leading causes of death worldwide and remains a major public health
challenge. The introduction of more sensitive and powerful technologies has permitted the …